

VITÆ

6

PREETI DESAI

Present Position : Sr.Scientist
Medicinal Chemistry
Zydus Research Centre
Sarkhej-Bavla NH#8A, Moraiya,
Ahmedabad 382210,
Gujarat, India
Email: preetiraval@zyduscadila.com,
preeti_raval@sify.com

ACADEMIC AND PROFESSIONAL CAREER: DEGREE/POSITION

B.Sc.Univ/Institution : South Gujarat University, Gujarat
Subject Studied : Chemistry
Year : 1989
M.Sc.Univ/Institution : South Gujarat University, Gujarat
Subject Studied : Chemistry (Organic)
Year : 1991

RESEARCH AND PROFESSIONAL EXPERIENCE

November 1991-till Date : Zydus Research Center
Sarkhej-Bavla NH#8A, Moraiya,
Ahmedabad 382210, Gujarat, India

PROFESSIONAL EXPERIENCE

Working for last 20 Years in the field of Drug Discovery, Medicinal Chemistry & Process Research in pharmaceutical industry.

No of patents : 8 No of publications : 6 No of posters : 6

RESEARCH SPECIALISATION

- Organic Synthesis of Biologically useful compounds.
- Extensive knowledge and hands in all areas of modern synthetic organic chemistry
- Designing New chemical entities based on Molecular modeling
- Designing Synthetic projects for making patentable New Chemical Entities, Execution of projects (Synthesis), Following of biological results to modify project based on structure activity correlation

- To study various targets in metabolic disorders segment to keep the track of existing targets as well as newly emerging targets
- Prior art search and Patent drafting

ACHIEVEMENTS

- Our group is successful in producing few lead molecules for diabetes and dislipidemia which are selected for further clinical evaluation. One of the NCE (ZY H1) has presently in Phase III clinical trials for dislipidemia, an other NCE (ZY H2) has completed phase I clinical trials successfully for type-2 diabetes.
- One of the NCE (ZY T1) Thyroid-beta agonist for the treatment of dyslipidemia and obesity is presently undergoing for Phase I clinical trials. Our group has generated excellent Intellectual property by filing number of patents and few papers in international journals are on the way to get published shortly.
- Developed multistep processes for Lansoprazole, Ticlopidine, Omeprazole, Meloxicam, Carvedilol, Sildenafil Citrate and Nicorandil up to Kilogram scale which are currently being used for manufacturing.

Publications :

1. Brijesh Kumar Srivastava, Amit Joharapurkar, Saurin Raval, Jayendra Z. Patel, Rina Soni, **Preeti Raval**, Archana Gite, Amitgiri Goswami, Nisha Sadhwani, Neha Gandhi, Harilal Patel, Bhupendra Mishra, Manish Solanki, Bipin Pandey, Mukul R. Jain, and Pankaj R. Patel. **Diaryl Dihydropyrazole-3-carboxamides with Significant In Vivo Antiobesity Activity Related to CB1 Receptor Antagonism: Synthesis, Biological Evaluation, and Molecular Modeling in the Homology Model.** *J. Med. Chem.* 2007, 50, 5951-5966.
2. Harikishore Pingali, Saurin Raval, **Preeti Raval**, Pankaj Makadia, Pandurang Zaware, Asish Goel, Dinesh Suthar, Mukul Jain and Pankaj Patel. **Novel Oxazole containing phenylpropane derivatives as Peroxisome Proliferator Activated Receptor agonists with hypolipidemic activity.** *Pharmazie* 63: 2008, 497-502.
3. Saurin Raval, **Preeti Raval**, Debdutta Bandyopadhyay, Krunal Soni, Digambar Yevale, Digvijay Jogiya, Honey Modi, Amit Joharapurkar, Neha Gandhi, Mukul R. Jain, Pankaj R. Patel. **Design and synthesis of novel 3-hydroxy-cyclobut-3-ene-**

- 1,2-dione derivatives as thyroid hormone receptor β (TR- β) selective ligands.** *Bioorganic & Medicinal Chemistry Letters* 18, (2008), 3919–3924.
4. **Preeti Raval**, Mukul Jain, Amitgiri Goswami, Sujay Basu, Archana Gite, Atul Godha, Harikishore Pingali, Saurin Raval, Suresh Giri, Dinesh Suthar, Maanan Shah, Pankaj Patel. **Revisiting glitazars : Thiophene substituted oxazole containing α -ethoxy phenyl propanoic acid derivatives as highly potent PPAR α/γ dual agonists devoid of adverse effects in rodents.** *Bioorganic & Medicinal Chemistry Letters* 21, (2011), 3103–3109.
 5. Saurin Raval, Mukul Jain, **Preeti Raval**, Niket Khare, Joharapurkar A, Dhote V, Bandyopadhyay D et.al **Modified 9H-fluorene-9-carboxamides as MTP-inhibitors.** *International Journal of Drug Design and Discovery, Volume 2 • Issue 4 • October– December 2011, 611-618.*
 6. Saurin Raval, **Preeti Raval**, Mukul Jain: **Emerging Therapies for Dyslipidemia: Known Knowns and Known Unknowns of MTP Inhibitors.** *Recent Patents on Endocrine, Metabolic & Immune Drug Discovery* 2012, 6, 24-29.

Patents :

1. Lohray Braj Bhushan; Lohray Vidya Bhushan; Barot Vijay Kumar; Raval Saurin Khimshankar; **Raval Preeti Saurin**; Basu Sujay. **Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine.** WO03009841, EP1414439, US6987123.
2. Lohray Braj Bhushan; Lohray Vidya Bhushan; Barot Vijay Kumar Gajubhai; Raval Saurin Khimshanker; **Raval Preeti Saurin**; Basu, Sujay. **Novel heterocyclic compounds having hypolipidemic, hypocholesteremic activities process for their preparation and pharmaceutical compositions containing them and their use in medicine.** US20030236254.
3. Raval Saurin; **Raval Preeti**; Lohray Braj Bhushan; Lohray Vidya Bhushan; Patel Pankaj Ramanbhai. **Selective TR-beta 1 agonist.** WO2007132475.
4. Raval Saurin; **Raval Preeti**; Lohray Braj Bhushan; Lohray Vidya Bhushan; Patel Pankaj Ramanbhai; **Selective TR-beta 1 agonist.** WO2008 062469.
5. Raval Saurin; **Raval Preeti**; **Thyroid Receptor Ligands**, WO2010049946.

6. Raval Saurin, *Raval Preeti*, Jain Mukul. **Thyroid Receptor Modulators**, WO2010086878.
7. *Preeti Raval*, Saurin Raval, **Thyroid Hormone Receptor Ligands**. (Filed in October 2011)
8. *Preeti Raval*, Saurin Raval, **Thyroid Hormone Receptor Ligands**. (Filed in November 2011)

Posters :

1. Sujay Basu, Saurin Raval, *Preeti Raval*, H.M. Kothari, V.G. Barot and Vidya Bhusan Lohray, Archana Patel, Mukul Jain. **Novel α -alkoxy β phenyl propanoic acid derivatives as potential hypolipidemic compounds having antidiabetic activity**. The Ramanbhai Foundation Ist International Symposium on "Current Trends in Pharmaceutical Sciences : Drug Discovery - Journey from Mouse to Man". January 23-24, 2003.
2. Saurin Raval, *Preeti Raval*, Sujay Basu, Atul Godha, Jayendra Patel, Vidya Lohray, Mukul Jain, Archana Patel. **Novel Pyrrole Containing Hypoglycemic and Hypotriglyceridemic Compounds**. The Ramanbhai Foundation IInd International Symposium on "Current Trends in Pharmaceutical Sciences : Role of genomics and proteomics". January 23-25, 2005.
3. Kiran Chauhan, Vipin Dhote, Samadhan Kshirsagar, Saurin Raval, *Preeti Raval*, Amit Johrapurkar and Mukul R. Jain. **Inhibition of VLDL Secretion Improves the Hyperlipidemia and Insulin Resistance in Genetically Obese Zucker fa/fa Rats**. The Ramanbhai Foundation IVth International Symposium on "Advances in Cardiometabolic Research - Basic Science and Clinical Aspects". February 2-5, 2009.
4. Krunal Soni, *Preeti Raval*, Saurin Raval, Debdutta Bandyopadhyay, Amit Johrapurkar, Digambar Yevale, Digvijay Jogiya, Jaymin Barot, Krishna Jadeja and Mukul R. Jain. **Design And Synthesis of Squaric Acid Derivatives as Thyroid Hormone Receptor β (TR β) Selective Ligands**. The Ramanbhai Foundation IVth International Symposium on "Advances in Cardiometabolic Research - Basic Science and Clinical Aspects". February 2-5, 2009.

5. Vipin Dhote, Samadhan Kshirsagar, Nirav Dhanesha, *Preeti Raval*, Saurin Raval, Pankaj Jain, Harilal Patel, Debdutta Bandyopadhyay, Amit Joharapurkar, Mukul Jain, and Pankaj R. Patel. **Microsomal triglyceride transfer protein inhibition influences insulin sensitivity and atherosclerosis risk in Zucker fatty rats.** 4th International Symposium on current trends in drug discovery research, Lucknow, 2010.
6. Kartikkumar N. Patel, Savita D. Patil, Amit Joharapurkar, Vipin Dhote, Samadhan Kshirsagar, Nirav Dhanesha, Avnish Patel, Vishal Patel, Kinjal Thakkar, Krishnarup Ghosh Dastidar, Debdutta Bandyopadhyay, *Preeti Raval*, and Mukul R. Jain. **Role of peripheral mechanisms in acute orexigenic effect of triiodothyronine.** The Ramanbhai Foundation Vth International Symposium on “Advances in Translational Research and Medicines”. February 1-4, 2011.